‘Biggest leap forward in decades’: Daily pill makes deadly cancer tumours disappear in major trial

A once-daily tablet called daraxonrasib has produced remarkable results in an early clinical trial when administered alongside chemotherapy.

Trials have shown it rendering tumours undetectable in roughly one in 12 patients with advanced pancreatic cancer.

The findings, unveiled at a European cancer research conference in Barcelona, have been hailed by Cancer Research UK as “the biggest leap forward we’ve seen in decades” for those facing one of the most lethal and treatment-resistant forms of the disease.

Michelle Mitchell, the charity’s chief executive, said the drug “could offer real hope to people facing one of the deadliest and most difficult-to-treat cancers.”

However, she stressed that additional trials would be required before the treatment could be considered for NHS use.

The phase one/two study enrolled 61 patients who had recently received diagnoses of advanced pancreatic cancer that had spread beyond the organ.

Among those given daraxonrasib in combination with chemotherapy, tumours shrank or vanished entirely in 60.7 per cent of cases, while disease progression was halted in 90.2 per cent of participants.

Survival rates were notably higher than those typically seen with standard treatment alone.

After one year, 76.6 per cent of patients in the trial remained alive.

This compares with an estimated 40 to 45 per cent for those receiving only chemotherapy.

The median follow-up period stood at 18 months, with the typical time before cancer resumed growing measured at 12.8 months.

Dr Wungki Park, the oncologist at Memorial Sloan Kettering Cancer Centre in New York who presented the findings, described the results as “a massive, massive breakthrough” in treating the disease.

He said: “In about one in 12 patients, it [the cancer] completely disappeared. And then with such a long follow-up, this is real. We’ve never seen such a thing.”

LATEST DEVELOPMENTS

Smoking now MORE socially acceptable than vaping in shock blow to Labour’s war on vapesAntidepressant prescriptions soar to record 9.1 million as MP warns of devastating side effects Boots to start prescribing medical cannabis in first for UK high street pharmacy

Asked whether those patients could be considered cured, Dr Park responded: “This is the closest to cure.”

Dr Madina Kara, head of research at Pancreatic Cancer UK, underscored the urgency of progress in this area.

She said: “Half of people with pancreatic cancer die within three months of diagnosis and their loved ones would give anything to spend more precious time with them.”

Daraxonrasib targets the mutated KRAS gene, present in more than nine out of 10 pancreatic tumours, which sends continuous signals that drive cancer cell growth.

By blocking this mechanism, the drug can prevent tumours from expanding further.

Its potential extends well beyond the pancreas.

Dozens of other cancer types, including lung and ovarian, carry similar mutations, raising hopes that the treatment could eventually benefit a far wider group of patients.

In the UK, more than 11,000 people receive a pancreatic cancer diagnosis annually, while upwards of 10,000 die from it each year.

It carries the lowest survival rate of any common cancer in Britain.

Researchers cautioned that cancer frequently develops resistance to drug therapies, and longer-term data remain essential before any conclusions about lasting remission can be drawn.

Leave a Comment

Scroll to Top